Wells Fargo Downgrades Pharmacyclics (PCYC) to Market Perform
Tweet
Share
E-mailGet Alerts PCYC Hot Sheet
Price: $261.25 --0%
Rating Summary:
5 Buy, 17 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 11 | New: 13
Rating Summary:
5 Buy, 17 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 11 | New: 13
Join SI Premium – FREE
Wells Fargo downgraded Pharmacyclics (NASDAQ: PCYC) from Outperform to Market Perform with a price target of $261.25. Analyst Matthew Andrews thinks there is a high likelihood its deal with Abbvie closes.
For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.
Shares of Pharmacyclics closed at $230.48 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Double Downgrades AU Optronics (2409:TT) (AUO) to Underweight
- UBS Downgrades Gujarat State Petronet (GUJS:IN) to Sell
- CLSA Downgrades Denso Corp. (6902:JP) (DNZOY) to Sell (5)
Create E-mail Alert Related Categories
DowngradesRelated Entities
Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
